SCYNEXIS Stock

SCYNEXIS Cash Conversion Cycle

Cash Conversion Cycle (CCC) of SCYNEXIS (SCYX) as of Aug 4, 2026.

Cash Conversion Cycle

0.00

Last updated:

Cash Conversion Cycle (CCC) of SCYNEXIS is 2026 0.00 . Cash Conversion Cycle (CCC) of SCYNEXIS was 2025 -167.01 . It decreases by % higher compared to the previous year.
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s SCYNEXIS with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

Profitability — SCYNEXIS

All Key Metrics — SCYNEXIS